Dr. Brendan Boostrom is currently a resident in veterinary medical oncology and Master’s student at the Colorado State University Flint Animal Cancer Center.
He received his B.S. in Animal Sciences from the University of Maryland, College Park, then his D.V.M from the University of California, Davis. During veterinary school, he pursued his passion for oncology, receiving outstanding student awards in both medical and radiation oncology. After a clinical internship at the University of Pennsylvania, he joined the Flint Animal Cancer Center in 2014.
Brendan’s primary research interests are personalized cancer treatment, metronomic therapy, drug repositioning, and biomarker analysis. Current projects includes a phase I clinical trial of dasatinib in tumor-bearing dogs, and growth inhibition of canine hemangiosarcoma by combining beta blockers and cytotoxic drugs.